

[Request Information](#)

[Permalink](#)

Treatment to protect and / or recover sexual function of the cavernosal nerve (sexual potency) after radical prostatectomy

Tech ID: 22229 / UC Case 2010-964-0

BRIEF DESCRIPTION

It is estimated that 1 in 6 men will be diagnosed with prostate cancer in their lifetime. One of the consequences of removing the prostate for prostate cancer is a non-permanent injury of the cavernosal nerve during open radical prostatectomy (RP) or robot-assisted radical prostatectomy (RARP), which may result in post-operative sexual dysfunction. These sexual side effects can severely affect the quality of life for men and their loved ones.

Researchers at the University of California, Irvine have developed a new use for an existing compound that can be used to prevent, mitigate, or treat erectile dysfunction associated with prostate removal surgery.

SUGGESTED USES

The compound may be used to treat erectile dysfunction in men who have undergone prostatectomy due to prostate cancer.

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	8,653,057	02/18/2014	2010-964

CONTACT

Richard Y. Tun
tunr@uci.edu
tel: 949-824-3586.



OTHER INFORMATION

KEYWORDS

Sexual dysfunction, Erectile dysfunction, Prostate cancer

CATEGORIZED AS

- » **Medical**
 - » Disease: Cancer
 - » Disease: Kidneys and Genito-Urinary System
 - » New Chemical Entities, Drug Leads
 - » Therapeutics

RELATED CASES

2010-964-0

UCI Beall
Applied Innovation

5270 California Avenue / Irvine, CA
92697-7700 / Tel: 949.824.2683



© 2012 - 2014, The Regents of the University of
California
[Terms of use](#)
[Privacy Notice](#)